HSP70 (Heat Shock Protein 70) inducer therapies represent a promising neuroprotective strategy targeting the proteostasis network in neurodegenerative diseases. HSP70 molecular chaperones play critical roles in protein folding, aggregate clearance, and cellular stress resistance. Enhancing HSP70 activity can mitigate proteostasis failure, a central hallmark of Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and other proteinopathies.
The HSP70 family includes multiple isoforms:
- HSPA1A/HSP70-1: Inducible stress response chaperone, primary target for pharmacological activation
- HSPA8/Hsc70: Constitutively expressed chaperone involved in protein folding and autophagy
- BiP/GRP78: ER-resident HSP70 involved in unfolded protein response
HSP70 functions include:
- ATP-dependent protein folding assistance
- Aggregate disassembly and clearance
- Co-chaperone regulation of client protein folding
- Targeting misfolded proteins for autophagy or proteasomal degradation
- Aggregate clearance: HSP70 binds to misfolded proteins (amyloid-beta, alpha-synuclein, TDP-43) and facilitates their clearance via autophagy
- Synaptic protection: Preserves synaptic proteins from misfolding and degradation
- Mitochondrial protection: Protects mitochondrial proteins and reduces ROS generation
- Anti-inflammatory: Reduces neuroinflammation by modulating microglial activation
Pharmacological upregulation of HSP70:
- Geldanamycin derivatives (17-DMAG, 17-AAG): HSP90 inhibitors that indirectly activate HSF1 and increase HSP70 expression
- HSF1 activators: Direct activation of heat shock factor 1 to drive HSP70 transcription
- Geranylgeranylacetone (GGA): FDA-approved HSP70 inducer used for gastric ulcers, being repurposed for neurodegeneration
Dietary and plant-derived HSP70 inducers:
- Curcumin: Polyphenol that activates HSF1 and upregulates HSP70
- Resveratrol: SIRT1 activator that enhances HSP70 expression via AMPK pathway
- Sulforaphane: NRF2 activator with secondary HSP70 induction
- Tat-HSP70 fusion peptides: Cell-penetrating peptides that deliver functional HSP70 domains
- Boss-C70: Engineered co-chaperone domain peptides that enhance HSP70 activity
| Dimension |
Score |
Rationale |
| Novelty |
7 |
Established target in oncology, relatively early for neurodegeneration |
| Mechanistic Rationale |
9 |
Direct proteostasis restoration, multi-disease relevance |
| Root-Cause Coverage |
8 |
Addresses protein aggregation at the chaperone level |
| Delivery Feasibility |
7 |
BBB-penetrating small molecules and natural compounds available |
| Safety Plausibility |
8 |
HSP70 induction is physiologically protective, good safety margin |
| Combinability |
9 |
Synergizes with autophagy inducers, proteasome modulators, anti-amyloid approaches |
| Biomarker Availability |
7 |
HSP70 levels can be measured in CSF and blood |
| De-risking Path |
7 |
Preclinical data strong; clinical trials in oncology de-risk safety |
| Multi-disease Potential |
9 |
AD, PD, ALS, Huntington's disease, FTD all have proteostasis deficits |
| Patient Impact |
8 |
Could benefit broad patient populations with proteinopathies |
| Total |
72 |
|
- Research Gap: Detailed next steps to be developed based on current evidence
- Expert Consultation: Seek input from domain specialists
- Evidence Review: Conduct systematic review of available data
- Phase 1 (0-6 months): Initial research and evidence gathering
- Phase 2 (6-12 months): Develop preliminary approach
- Phase 3 (12-24 months): Refine and validate approach